AbbVie sees acquired IPR&D, milestone expenses negatively impacting Q3 results by $0.02

News
2 months ago
0 likes
0 comments
AbbVie sees acquired IPR&D, milestone expenses negatively impacting Q3 results by $0.02

Published Wednesday 5 October 2022

AbbVie (NYSE:ABBV) said that its Q3 2022 financial results will include an acquired IPR&D and milestones expense of $40 million on a pre-tax...

Full story at Seeking Alpha

Economy Financial Reports Industry Markets Nyse

Details About the Article "AbbVie sees acquired IPR&D, milestone expenses negatively impacting Q3 results by $0.02"

This article was originally published by Seeking Alpha and was recommended by Finances48.com a couple of days later due to its popularity. It has gotten a lot of attention and 0 comments have been submitted since it was published in October of 2022. The article "AbbVie sees acquired IPR&D, milestone expenses negatively impacting Q3 results by $0.02" is a news post and categorized as Finance by finances48.com and the main topics includes Economy, Financial Reports, Industry, Markets & Nyse.

Similar Sites Recommend for You

We at finances48.com have gathered similar sites that might be interesting for you.

finances48.com is the best news aggregator website on the web for news about finance.